March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Intravitreal Administration of FP-MC, Inhibitor of Nuclear Factor KB, Reduced Retinal Immunoreactivity of TNF-a, IL-17, c-PLA2, and GFAP in Type 1 Diabetic Rats
Author Affiliations & Notes
  • Juan P. Salica
    Ophthalmology, Universidad Austral, Pilar, Argentina
  • Jorge E. Mancini
    Ophthalmology, Facultad de Ciencias Biomedicas, Buenos Aires, Argentina
  • Eduardo Chuluyan
    Pharmacology, Universidad de Buenos Aires, Buenos Aires, Argentina
  • Paulo Maffia
    Pharmacology, Universidad de Buenos Aires, Buenos Aires, Argentina
  • Diego Guerrieri
    Pharmacology, Universidad de Buenos Aires, Buenos Aires, Argentina
  • Juan E. Gallo
    Ophthalmology, Hospital Universitario Austral, Pilar, Argentina
  • Footnotes
    Commercial Relationships  Juan P. Salica, None; Jorge E. Mancini, None; Eduardo Chuluyan, None; Paulo Maffia, None; Diego Guerrieri, None; Juan E. Gallo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2794. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Juan P. Salica, Jorge E. Mancini, Eduardo Chuluyan, Paulo Maffia, Diego Guerrieri, Juan E. Gallo; Intravitreal Administration of FP-MC, Inhibitor of Nuclear Factor KB, Reduced Retinal Immunoreactivity of TNF-a, IL-17, c-PLA2, and GFAP in Type 1 Diabetic Rats. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2794.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We have previously shown that topical administration of SLPI and FP-MC stongly reduced corneal inflammation and neovascularization in rats and rabbits. In the present study we aim at examining the expression of proinflammatory citokines in the retina of type 1 diabetic rat treated with FP-MC.

Methods: : Eight male Wistar rats of 250gr were treated with an intraperitoneal injection of 45mg/kg of streptozotocin. Only animals with glycemia levels above 200mg/dl were included in the study. The animals were divided into two groups of 4 rats. One group was treated with an intravitreal injection of 4ul of FP-MC (0,2 ug/ul) at 26 weeks of diabetes and the remaining four animals received buffer as treatment. Eight non-diabetic rats with the same age of diabetics were used as a control group. Animals were sacrificed after 30 weeks of diabetes. Cross sections of retinas were analyzed by immunohistochemistry using primary antibodies against GFAP, TNF-alfa, IL-17, cPLA2 and GFAP.

Results: : Immunostaining of the analyzed antibodies were up-regulated in diabetic animals without treatment. Diabetic rats treated with FP-MC showed up a pattern and immunostaining similar to that seen in the control group.

Conclusions: : Results suggest that FP-MC modulates inflammatory markers in type 1 diabetic rats. The fusion protein may be a suitable agent to test in diabetic retinopathy development.

Keywords: inflammation • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×